Neoadjuvant chemotherapy improves survival compared with concurrent chemoradiation alone in nasopharyngeal carcinoma patients with N3 disease. Issue 12 (14th September 2019)

• Record Type: Journal Article
• Authors: Han, James E.; Yi, Sun K.; Wang, Steven; Erman, Audrey; Bearelly, Shethal; Sindhu, Simran; Robbins, Jared R.; Bauman, Julie; Hsu, Charles C.
• Is Part Of: Head & neck. Volume 41:Issue 12(2019)
• Page Start: 4076
• Page End: 4087
• Publication Date: 2019-09-14
• Subjects: chemoradiation -- head and neck cancer -- nasopharyngeal carcinoma -- neoadjuvant chemotherapy -- radiation therapy; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.25955
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Background: Neoadjuvant chemotherapy (NAC) trials in endemic regions of nasopharyngeal carcinoma (NPC) found improved survival, but studies are lacking in nonendemic regions. We assessed whether adding NAC to concurrent chemoradiation (CRT) improves overall survival (OS), especially in high‐risk nonendemic patients. Methods: Definitively treated NPC patients (n = 5424) from the National Cancer Database were analyzed for predictors of NAC and NAC effects on OS with multivariate Cox proportional hazards analysis (multivariate analysis [MVA]). Propensity score matched (1:2) survival analysis of NAC (n = 968) and CRT alone (n = 1914) was also performed. Effects on OS were stratified by risk group. Results: On MVA, NAC‐improved OS among the total cohort (hazard ratio [HR] 0.89, P = .049), particularly among stratified keratinizing histology (HR 0.82, P = .015) and N3 disease (HR 0.73, P = .046). Among propensity matched patients, NAC improved OS in patients with N3 disease (n = 336; HR 0.71, P = .046). Conclusions: NAC may improve OS among nonendemic NPC patients at higher risk of distant micrometastases, particularly N3 disease and those with unfavorable histology.